TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences, have collaborated to introduce CleanScribe™ RNA Polymerase. This novel enzyme reduces the formation of double-stranded RNA (dsRNA) by up to 85% during in vitro transcription (IVT) for mRNA production, a key
ST Pharm and Quantoom Biosciences have announced an extended collaboration to advance the development and manufacturing of RNA-based vaccines and therapeutics. This partnership integrates the complementary strengths of both companies to enhance the global supply of critical RNA manufacturing technologies.
Touchlight, an innovation-driven CDMO, has entered into a license agreement with GSK, a leader in biopharmaceutical innovation. This agreement grants GSK non-exclusive rights to use Touchlight’s proprietary enzymatic dbDNA (doggybone DNA) technology for the development and production of mRNA-based products.
Aldevron, a global manufacturer of DNA, RNA, and proteins, has announced a strategic partnership with Acuitas Therapeutics, a private biotechnology company that specialises in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNPs). The collaboration
The emerging field of mRNA therapeutics is still young. This class of therapeutics is poised to have broad implications in the treatment of many indications in addition to infectious diseases such as cancer, autoimmune diseases, and cardiovascular diseases, as well
TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, has announced the opening of its new cGMP mRNA manufacturing facility in San Diego. The facility, spanning 32,000 square feet, has been specifically designed to
BioCentriq, a cell therapy Contract Development and Manufacturing Organisation (CDMO), has announced a significant enhancement to its partnership with Pluristyx Inc., an early-stage biotechnology company specialising in Induced Pluripotent Stem Cell (iPSC) products. Pluristyx’s unique clinical-grade iPSC lines, derived from
Lonza and Oxford Nanopore Technologies have announced a collaboration to cGMP validate and commercialise a novel test to accelerate the analysis of mRNA products. The announcement was made on Tuesday, 30th January 2024. The partnership aims to enable advanced and innovative analysis for multiple
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
